Role of Metformin in Polycystic Ovary Syndrome
DOI:
https://doi.org/10.12775/JEHS.2024.52.009Keywords
ovulation, Polycystic Ovary Syndrome, Metformin, Insulin ResistanceAbstract
Introduction and purpose:
PCOS is identified by the presence of underdeveloped follicles in the ovaries caused by a lack of ovulation, and it is linked to heightened production of androgens in the ovaries. The observable symptoms of PCOS encompass irregular or absent menstrual cycles, obesity, and indications of excess androgens such as acne or oily skin. Metformin could be advantageous for a specific group of women with PCOS.
The aim of this study is to summarize the current knowledge regarding the effectiveness of metformin in the treatment of PCOS based on available scientific literature.
A brief description of the state of knowledge:
Metformin indirectly aids in enhancing ovulation and alleviating long-term metabolic issues, although its impact is considered moderate. Metformin also diminishes the levels of particular markers linked to arterial issues and chronic inflammation beneath the surface. This indicates a potential decrease in the continual risks of type 2 diabetes (DM) and cardiovascular disease (CVD) for women dealing with PCOS.
Summary (conclusions):
Managing PCOS involves personalized targets due to its diverse nature. In clinical practice, metformin is a recommended first step for managing PCOS in overweight or obese patients, particularly when oral contraceptives are not suitable or insulin resistance is evident.
References
Sanchez-Rangel E., Inzucchi S.E. Metformin: Clinical use in type 2 diabetes. Diabetologia. 2017;60:1586–1593.
Paneni F., Lüscher T.F. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. Am. J. Cardiol. 2017;120:S17–S27.
Marshall S.M. 60 years of metformin use: A glance at the past and a look to the future. Diabetologia. 2017;60:1561–1565.
Johnson J.A., Majumdar S.R., Simpson S.H., Toth E.L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25:2244–2248.
Anisimov V.N. Metformin: Do we finally have an anti-aging drug? Cell Cycle. 2013;12:3483–3489.
Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. nsulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2010:CD003053.
Fulghesu AM, Romualdi D, Di Florio C, Sanna S, Tagliaferri V, Gambineri A, et al. Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study. Hum Reprod. 2012;27(10):3057–3066.
Palomba S, Falbo A, Zullo F, Orio F., Jr Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009;30:1–50.
Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003;46:325–40.
Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother 2002;3:1177–89.
Tosca L, Solnais P, Ferre P, Foufelle F, Dupont J. Metformin-induced stimulation of adenosine 5′ monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. Biol Reprod. 2006;75:342–351.
Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Ewens KG, Spielman RS, Leppert PC, Myers ER. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab. 2008;93:792–800.
Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012 Mar;122(6):253-70. doi: 10.1042/CS20110386. PMID: 22117616; PMCID: PMC3398862.
Norman RJ, Davies MJ, Lord J, Moran LJ. The lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002;13: 251-7.
Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-36.
Balen AH. PCOS, obesity, and reproductive function: RCOG special study group on obesity. London: RCOG Press; 2007.
Azziz R, Ehrmann DA, Legro RS, et al. Tro- glitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin En- docrinol Metab 2001;86:1626-32.
Sepilian V, Nagamani M. Effects of rosigli- tazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005;90:60-5.
Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008;358:47-54.
Tan S, Hahn S, Benson S, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 2007;157:669-76.
Talbott EO, Zborowski JV, Boudreaux MY, McHugh-Pemu KP, Sutton-Tyrrell K, Guzick DS. The relationship between C-reactive pro- tein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syn- drome. J Clin Endocrinol Metab 2004;89: 6061-7.
Legro RS, Azziz R, Ehrmann D, Fereshetian AG, O’Keefe M, Ghazzi MN. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sen- sitivity with troglitazone. J Clin Endocrinol Metab 2003;88:5137-44.
Essah PA, Wickham EP, Nestler JE. The metabolic syndrome in polycystic ovary syn- drome. Clin Obstet Gynecol 2007;50:205-25.
Torie Comeaux Plowden M.D. Eunice Kennedy Shriver National Institute of Child Health and Human Development; 2016. M.P.H. Reproductive endocrinology and infertility.
Teede H.D.A., Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8(1)
Ricardo Azziz M.D. M.P.H. Introduction: determinants of polycystic ovary syndrome. Fertil Steril. 2016;106(July (1)) [PubMed] [Google Scholar] [Ref list]
Ranjith reddy K. POLYCYSTIC Ovary Syndrome: ROLE OF AROMATASE GENE VARIANTS IN SOUTH INDIAN WOMEN. Int J Pharma Bio Sci. 2015;6(2)
Wołczyński S, Zgliczyński W. Abnormalities of the menstrual cycle. In: Large Interna – Endocrinology. 2nd edition. Medical Tribune Poland, Warsaw 2012, 561–567.
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus work- shop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47. doi: 10.1093/humrep/deh098.
Erin Barthelmess Rajesh KN. Polycystic ovary syndrome: Current status and future perspective. Front Biosci. 2014;6:104–119. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341818/.
Krępuła K, Bidzińska-Speichert B, Lenarcik A, Tworowska-Bardziń- ska U. Psychiatric disorders related to polycystic ovary syndrome. Pol J Endocrinol. 2012;63(6):488–491.
Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What's new? Adv Clin Exp Med. 2017 Mar-Apr;26(2):359-367. doi: 10.17219/acem/59380. PMID: 28791858.
Lord JM, Flight IH, Norman RJ. Insulin-sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;3:CD003053. Review.
Salpeter SR, Buckley NS, Kahn JA, Sal- peter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008;121:149-57.
Sahin I, Serter R, Karakurt F, et al. Met- formin versus flutamide in the treatment of met- abolic consequences of non-obese young women with polycystic ovary syndrome: a ran- domized prospective study. Gynecol Endocrinol 2004;19:115-24.
Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syn- drome. Diabetes Care 2007;30:471-8.
Lakhani K, Prelevic GM, Seifalian AM, Ati- omo WU, Hardiman P. Polycystic ovary syn- drome, diabetes and cardiovascular disease: risk and risk factors. J Obstet Gynaecol 2004;24:613-21.
Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z, Komsuoglu B. Effects of rosiglita- zone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 2005;153:115-9.
Topcu S, Tok D, Caliskan M, et al. Met- formin therapy improves coronary microvascu- lar function in patients with polycystic ovary syn- drome and insulin resistance. Clin Endocrinol (Oxf) 2006;65:75-80.
Barbieri RL. Clomiphene versus metformin for ovulation induction in polycystic ovary syn- drome: the winner is. . .. J Clin Endocrinol Metab 2007;92:3399-401.
Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551-66.
Giudice LC. Endometrium in PCOS: im- plantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab 2006; 20:235-44.
Palomba S, Russo T, Orio F Jr, et al. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum Reprod 2006;21:457-65.
Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syn- drome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893-902.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Karolina Nowak, Karolina Nowak, Zuzanna Olejarz, Zuzanna Drygała, Julia Wyrwał, Zuzanna Zielińska, Magdalena Słowik, Maria Nieć, Katarzyna Gierlach, Martyna Krasuska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 588
Number of citations: 0
